Published Date: 17 Mar 2023
A group of researchers from the annual meeting of the American Academy of Orthopedic Surgeons (AAOS) "analyzed the data and...
Read Full NewsTake 5 minutes to catch up on NeurologyLive®'s highlights from the week ending February 6, 2026.
A new comparison study of patients with autoimmune diseases reported high rates of anxiety and depression, with notable differences in when psychiatric symptoms emerged relative to disease onset.
A real-world study showed that cladribine tablets were associated with greater treatment persistence and lower health care costs in patients with multiple sclerosis compared with other common therapies.
The single-arm CLAD-MAPET study is evaluating whether cladribine tablets reduce microglial activation, captured by [F-18]PBR06-PET, in patients with MS experiencing progression without relapse or MRI activity on anti-CD20 therapy.
Delay Discounting Fails to Predict MDD Relapse, Q&A With Giles Story, PhD
The HCPFive: Top News for Healthcare Providers from the Week of 02/01
HCPLive 5 Stories in Under 5: Week of 02/01
1.
Studies have shown that physical activity prevents cancer in patients who have been treated for cancer in the past.
2.
Disparities in use of MRI to detect prostate cancer: Race and location may influence testing
3.
Including Isatuximab with a Standard Backbone Enhances Multiple Myeloma Results.
4.
GLP-1 Receptor antagonists used in a study allay fears about thyroid cancer.
5.
In breast cancer patients with nodes positive, preoperative hydroxyprogesterone may enhance disease-free survival.
1.
Hepatocellular Carcinoma: Progress in Detection, Pathogenesis, and Treatment
2.
Different Types of Blood Dyscrasias
3.
Managing Hematoma: A Guide to Prevention and Treatment
4.
Exploring the Benefits of Endari: How This Natural Remedy Can Help You Live a Healthier Life
5.
All You Need To Know About Partial Thromboplastin Time (PTT) Test
1.
International Lung Cancer Congress®
2.
Genito-Urinary Oncology Summit 2026
3.
Future NRG Oncology Meeting
4.
ISMB 2026 (Intelligent Systems for Molecular Biology)
5.
Annual International Congress on the Future of Breast Cancer East
1.
Breaking Ground: ALK-Positive Lung Cancer Front-Line Management - Part II
2.
Management of 1st line ALK+ mNSCLC (CROWN TRIAL Update) - Part V
3.
What Therapy Would Yield the Best Outcomes In Patients with R/R B-cell ALL?
4.
Newer Immunotherapies for Myeloma- A Comprehensive Overview- Part II
5.
Cost Burden/ Burden of Hospitalization For R/R ALL Patients
© Copyright 2025 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation